M M Regan
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein H, Gnant M, Winer E, Senn H, Regan M, Poortmans P, Weber W, Thürlimann B, Curigliano G, Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32:1216-1235.
Jul 6, 2021Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Jul 6, 2021Ann Oncol 2021; 32:1216-1235
Burstein H J, Gnant M, Winer E P, Senn H J, Regan M M, Poortmans P, Weber W P, Thürlimann Beat, Curigliano G, Panelists of the St Gallen Consensus Conference
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Luen S, Regan M, Colleoni M, Di Leo A, Viale G, Thürlimann B, Hackl W, Demanse D, Biasi O, Dell'orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Ann Oncol 2020; 31:1359-1365.
Jul 8, 2020Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Jul 8, 2020Ann Oncol 2020; 31:1359-1365
Luen S J, Regan M M, Colleoni M, Di Leo A, Viale G, Thürlimann Beat, Hackl W, Demanse D, Biasi O M, Dell'orto P, Kammler R, Savas P, Lee C K, Asher R, Loi S
Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.
Dec 4, 2019Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Dec 4, 2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2019; 30:1181.
Jul 1, 2019De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Jul 1, 2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2018; 29:2153.
Oct 1, 2018De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Oct 1, 2018Ann Oncol 2018; 29:2153
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Curigliano G
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2017
Dec 8, 2017A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Dec 8, 2017Ann Oncol 2017
Gennari A, Bernhard J, Morales S Murillo, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub Ursula, Colleoni M, Kennedy M J, von Moos R, Cortes J, Vidal M J, Hennessy B, Jerusalem G
Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017
Sep 25, 2017Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Sep 25, 2017Ann Oncol 2017
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson Per, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Bonnefoi H, Curigliano G
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017; 28:2225-2232.
Sep 1, 2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Sep 1, 2017Ann Oncol 2017; 28:2225-2232
Regan M M, Goldhirsch A, Coates A S, Gelber R D, Abdi E A, Ruhstaller Thomas, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H L, Láng I, Fleming G F, Francis P A, Walley B A, Pagani O
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
Aug 1, 2017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Aug 1, 2017Ann Oncol 2017; 28:1700-1712
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.
Jun 14, 2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Jun 14, 2012Ann Oncol 2012; 23:2843-51
Huober Jens, Regan M M, Gelber R D, Price K N, Öhlschlegel Christian, Viale G, Coates A S, Goldhirsch A, Gelber S, Thürlimann Beat
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
Feb 18, 2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Feb 18, 2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009; 21:245-54.
Jul 24, 2009Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Jul 24, 2009Ann Oncol 2009; 21:245-54
Viale G, Goldhirsch A, Gelber R D, Öhlschlegel Christian, Karlsson P, Crivellari D, Golouh R, Brown R W, Price K N, Regan M M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M G, Maiorano E, Gusterson B A, Giobbie-Hurder A, Coates A S
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Regan M, SOFT/TEXT/PERCHE Steering Committee, Gelber R, Goldhirsch A, Coates A, Castiglione-Gertsch M, Maibach R, Thürlimann B, Price K, Fleming G, Francis P, Perez E, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19:1231-41.
Jul 1, 2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Jul 1, 2008Ann Oncol 2008; 19:1231-41
Regan M M, SOFT/TEXT/PERCHE Steering Committee, Gelber R D, Goldhirsch A, Coates A S, Castiglione-Gertsch M, Maibach R, Thürlimann Beat, Price K N, Fleming G F, Francis P, Perez E A, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group